Jump to main content
Jump to site search

Issue 7, 2013
Previous Article Next Article

Lonidamine and related impurities: HPLC analysis, stability profile and degradation pathways

Author affiliations

Abstract

A sensitive HPLC-DAD method for the simultaneous determination of the anticancer lonidamine and five potential impurities in pure powder and tablet dosage forms was developed and validated. The impurities comprised by-products from thermal and photodegradation and potential secondary products from the drug synthesis. The structure of the main drug impurity was elucidated with the aid of GC-MS chromatography. A good resolution of all the analytes was achieved on a Gemini C18 column using isocratic elution and DAD detection. The optimal mobile phase consisted of a mixture of methanolphosphate buffer (pH 3) (80 : 20, v/v). At a flow rate of 1.5 ml min−1, the total time of analysis was less than 15 min. The method was determined to be linear in the range of 10–200 μg ml−1 for the quantitation of lonidamine and 0.5–50 μg ml−1 for the related substances with a detection limit of 0.15 μg ml−1 for the impurities. Percentage recoveries ranged from 97.4 to 102.3 and 95.7 to 103.5 for the drug and impurities, respectively, and the relative precision values were less than 3.3%. Finally, the method was demonstrated to be robust, resistant to small variations of chromatographic variables such as pH, mobile phase organic/aqueous composition and column temperature.

Graphical abstract: Lonidamine and related impurities: HPLC analysis, stability profile and degradation pathways

Back to tab navigation

Article information


Submitted
28 Nov 2012
Accepted
11 Feb 2013
First published
11 Feb 2013

Anal. Methods, 2013,5, 1715-1720
Article type
Paper

Lonidamine and related impurities: HPLC analysis, stability profile and degradation pathways

G. Ioele, M. De Luca and G. Ragno, Anal. Methods, 2013, 5, 1715
DOI: 10.1039/C3AY26467J

Social activity

Search articles by author

Spotlight

Advertisements